Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05527184 · ClinicalTrials.gov registry record · Phase 1

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

A Phase 1 study of Endometrial Cancer and Cervical Cancer, sponsored by AbbVie.

Active
Registry status
Phase 1
Development phase
256
Enrollment target
20
Study locations

NCT05527184 is a Phase 1 study of Endometrial Cancer and Cervical Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 256 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05527184, a Phase 1 study of Endometrial Cancer and Cervical Cancer, is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
256 participants
Enrollment target
20
Study locations

Study Summary

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.

Conditions Studied

Endometrial Cancer Cervical Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma High Grade Serous Adenocarcinoma of Ovary

Interventions

  • DRUG IMGN151

Study Locations (20)

California

  • City of Hope National Medical Center /ID# 269036 - Duarte
  • Moores Cancer Center /ID# 269040 - La Jolla
  • University of California Los Angeles Medical Center /ID# 269037 - Los Angeles
  • Hoag Memorial Hospital Presbyterian /ID# 269047 - Newport Beach

Florida

  • AdventHealth Celebration /ID# 269030 - Kissimmee
  • Mount Sinai Medical Center /ID# 269050 - Miami
  • Miami Cancer Institute at Baptist Health /ID# 269041 - Miami
  • Florida Cancer Specialists- Sarasota Cattlemen /ID# 269055 - Sarasota

New York

  • Roswell Park Cancer Institute /ID# 269043 - Buffalo
  • Long Island Jewish Medical Center /ID# 269035 - New Hyde Park
  • Columbia University Irving Medical Center /ID# 269033 - New York

Massachusetts

  • Massachusetts General Hospital /ID# 278119 - Boston
  • Dana-Farber Cancer Institute /ID# 269039 - Boston

Alabama

  • University of Alabama at Birmingham /ID# 269045 - Birmingham

Colorado

  • UCHSC Anschultz Cancer Pavilion /ID# 269056 - Aurora

Illinois

  • University of Chicago Medical Center /ID# 269028 - Chicago

Michigan

  • Karmanos Cancer Institute - Detroit /ID# 269052 - Detroit

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2023-01-11
Est. Completion 2027-02
Phase Phase 1

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05527184

The ClinicalTrials.gov registry entry for NCT05527184 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (51% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMGN151 is the first listed.

NCT05527184 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT05527184 about?

NCT05527184 is a clinical study titled "First in Human Study of IMGN151 in Recurrent Gynaecological Cancers". IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; r...

What is the current status of trial NCT05527184?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 256 participants. The study started on 2023-01-11. Estimated completion is 2027-02.

What conditions does trial NCT05527184 study?

This clinical trial studies the following conditions: Endometrial Cancer, Cervical Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma of Ovary.

What interventions are being tested in trial NCT05527184?

The interventions under investigation include: IMGN151 (DRUG).

Who is sponsoring clinical trial NCT05527184?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05527184 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Cervical Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.